Bristol-Myers Squibb Company Ce
CELG-RI · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12 | $12 | $11 | $12 |
| % Growth | -0.4% | 9.5% | -9.2% | – |
| Cost of Goods Sold | $4 | $4 | $4 | $5 |
| Gross Profit | $8 | $8 | $7 | $7 |
| % Margin | 66% | 65.8% | 65.5% | 60.2% |
| R&D Expenses | $3 | $3 | $2 | $3 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | $0 |
| Operating Expenses | $4 | $4 | $4 | $5 |
| Operating Income | $4 | $4 | $4 | $3 |
| % Margin | 31.5% | 33.6% | 31.4% | 20.5% |
| Other Income/Exp. Net | -$1 | -$2 | -$1 | -$2 |
| Pre-Tax Income | $3 | $2 | $3 | $0 |
| Tax Expense | $1 | $0 | $1 | $0 |
| Net Income | $2 | $1 | $2 | $0 |
| % Margin | 18% | 10.7% | 21.9% | 0.6% |
| EPS | 1.08 | 0.64 | 1.21 | 0.036 |
| % Growth | 68.8% | -47.1% | 3,308.5% | – |
| EPS Diluted | 1.08 | 0.64 | 1.2 | 0.035 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $2 |
| EBITDA | $5 | $3 | $4 | $3 |
| % Margin | 37.8% | 26.8% | 40.1% | 20.6% |